Correct Answer: B. Esophageal dysmotility
The key discriminator is understanding the phenotypic differences between limited cutaneous systemic sclerosis (lcSSc, formerly CREST) and diffuse cutaneous systemic sclerosis (dcSSc). While both are manifestations of systemic sclerosis, their organ involvement patterns differ significantly.
Esophageal dysmotility is MORE common in lcSSc because it is a hallmark feature of the CREST syndrome (Calcinosis, Raynaud's, Esophageal dysmotility, Sclerodactyly, Telangiectasia). The smooth muscle of the esophagus is affected in approximately 75–90% of lcSSc patients, leading to dysphagia, reflux, and stricture formation. This occurs due to fibrosis and smooth muscle atrophy in the lower two-thirds of the esophagus, which is innervated by the vagus nerve and is particularly vulnerable in lcSSc.
In contrast, dcSSc is characterized by early, aggressive visceral organ involvement, particularly the lungs and kidneys, rather than prominent esophageal disease. The pathophysiology in dcSSc involves rapid collagen deposition in skin and internal organs, with interstitial lung disease (ILD) and scleroderma renal crisis (SRC) being the defining complications that drive morbidity and mortality in dcSSc.
The clinical pearl: lcSSc patients often present with long-standing Raynaud's phenomenon and slowly progressive skin changes limited to the face and hands, with esophageal involvement being a frequent early manifestation. dcSSc patients, by contrast, present with rapid diffuse skin thickening and early visceral crises. Indian rheumatology practice recognizes this distinction as critical for prognostication and surveillance strategies.
Why the other options are wrong
A. Interstitial lung disease — This is wrong because ILD is MORE common in dcSSc, not lcSSc. ILD occurs in 40–75% of dcSSc patients and is a leading cause of death, whereas it affects only 20–30% of lcSSc patients. The aggressive fibrotic phenotype of dcSSc drives early pulmonary involvement. NBE may trap students who know 'systemic sclerosis causes ILD' but forget the disease subtype distinction. C. Myopathy — This is wrong because myopathy is NOT a characteristic feature of either lcSSc or dcSSc. While inflammatory myositis can overlap with systemic sclerosis (systemic sclerosis–myositis overlap), it is not a defining or more common feature in lcSSc. Muscle involvement in systemic sclerosis is rare and typically indicates overlap with other connective tissue diseases. D. Scleroderma renal crisis — This is wrong because SRC is MORE common in dcSSc, not lcSSc. SRC occurs in 10–15% of dcSSc patients (especially within the first 5 years) but is rare in lcSSc (<1%). SRC is a hallmark of aggressive dcSSc and is associated with anti-RNA polymerase III antibodies. NBE may trap students who know SRC is serious but forget it is a dcSSc complication.
High-Yield Facts
- CREST syndrome (Calcinosis, Raynaud's, Esophageal dysmotility, Sclerodactyly, Telangiectasia) is the clinical hallmark of limited cutaneous systemic sclerosis and esophageal involvement is present in 75–90% of lcSSc patients.
- Diffuse cutaneous systemic sclerosis is defined by rapid skin thickening proximal to elbows/knees and early visceral crises (ILD in 40–75%, SRC in 10–15%), making it the aggressive phenotype.
- Anti-centromere antibodies (ACA) are associated with lcSSc and predict better prognosis; anti-topoisomerase I (anti-Scl-70) and anti-RNA polymerase III are associated with dcSSc and poor prognosis.
- Esophageal dysmotility in lcSSc affects the lower two-thirds (smooth muscle) and causes reflux, strictures, and Barrett's esophagus; surveillance and PPI therapy are standard Indian clinical practice.
- Scleroderma renal crisis (acute kidney injury, hypertensive emergency) is a medical emergency in dcSSc and requires ACE inhibitor therapy; it is rare in lcSSc and indicates poor prognosis.
Mnemonics
CREST = lcSSc Calcinosis, Raynaud's, Esophageal dysmotility, Sclerodactyly, Telangiectasia — all features of limited cutaneous systemic sclerosis. Use this to remember that esophageal involvement is a hallmark of lcSSc. dcSSc = Diffuse + Deadly Diffuse skin involvement + Deadly visceral crises (ILD, SRC, cardiac involvement). Remember: dcSSc = early, aggressive, organ-threatening. lcSSc = slow, skin-limited, esophageal-prominent.
NBE Trap
NBE pairs systemic sclerosis with visceral complications (ILD, SRC) to lure students into choosing options A or D, forgetting that these are dcSSc features. The trap is conflating "systemic sclerosis" with "diffuse" systemic sclerosis — lcSSc is often overlooked as a distinct, less aggressive phenotype with esophageal predominance.
Clinical Pearl
In Indian rheumatology clinics, lcSSc patients typically present with long-standing Raynaud's phenomenon and are often diagnosed late because skin changes are limited to the face and hands. Esophageal dysmotility is frequently the first visceral manifestation and should trigger PPI therapy and dietary modification to prevent aspiration and Barrett's esophagus — a common complication in our patient population.
_Reference: Robbins Ch. 4 (Connective Tissue Disorders); Harrison Ch. 280 (Systemic Sclerosis)_